Literature DB >> 30271097

Hypertensive Crisis and Refractory Hypertension Caused by Atypical Hemolytic Uremic Syndrome and Effect of Eculizumab.

Fan-Yu Chen1, Chen-Huan Chen1,2,3,4, Chih-Ching Lin1,4.   

Abstract

Entities:  

Year:  2018        PMID： 30271097      PMCID： PMC6160511          DOI： 10.6515/ACS.201809_34(5).20180326D

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN： 1011-6842            Impact factor:   2.672


× No keyword cloud information.
  9 in total

Review 1.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

2.  Syndromes of thrombotic microangiopathy.

Authors:  James N George; Carla M Nester
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

3.  Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension.

Authors:  Toshiyuki Ohta; Kohtaro Urayama; Yoshihiro Tada; Takeki Furue; Sayaka Imai; Keita Matsubara; Hiroaki Ono; Takashi Sakano; Kazuhiko Jinno; Yoko Yoshida; Toshiyuki Miyata; Yoshihiro Fujimura
Journal:  Pediatr Nephrol       Date:  2014-10-16       Impact factor: 3.714

4.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

Review 5.  HUS and atypical HUS.

Authors:  T Sakari Jokiranta
Journal:  Blood       Date:  2017-04-17       Impact factor: 25.476

Review 6.  Atypical hemolytic uremic syndrome.

Authors:  Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Orphanet J Rare Dis       Date:  2011-09-08       Impact factor: 4.123

7.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Authors:  Christoph Licht; Larry A Greenbaum; Petra Muus; Sunil Babu; Camille L Bedrosian; David J Cohen; Yahsou Delmas; Kenneth Douglas; Richard R Furman; Osama A Gaber; Timothy Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe M Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

Review 8.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

9.  Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome.

Authors:  V Raghunathan; S K Sethi; M A Dragon-Durey; M Dhaliwal; R Raina; P Jha; S B Bansal; V Kher
Journal:  Indian J Nephrol       Date:  2017 Mar-Apr
  9 in total
  1 in total

Review 1.  Complement in Secondary Thrombotic Microangiopathy.

Authors:  Lilian Monteiro Pereira Palma; Meera Sridharan; Sanjeev Sethi
Journal:  Kidney Int Rep       Date:  2020-10-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.